Lubochna, Slovakia
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Phase
1/2Span
203 weeksSponsor
Immunocore LtdAnderlecht
Recruiting
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
Phase
N/ASpan
80 weeksSponsor
TakedaAnderlecht
Recruiting
Transfusion Surveillance in Anaesthesia
the aim of this register is to collect exhaustively the different data available surrounding a transfusion act in the context of an active haemorrhage. The aim is to allow different modelling and analysis related to emergency transfusion. Patients will be informed at the time of the anaesthesia consultation about the inclusion in the registry. The data will be collected from the patients' files by the investigators of the centre without modifying their management. The data collection period will not exceed the period of acute management.
Phase
N/ASpan
435 weeksSponsor
Erasme University HospitalAnderlecht
Recruiting
Comparison of Skeletal Effects of Herbst and Invisalign MA in Growing Patients With KLass II Malocclusion
Precise description of study methodology. For each group, a sample of +- 15 patients with class 2 malocclusion aged between 9 and 15 years will be collected for this prospective study who presented for an initial orthodontic consultation between October 2022 and july 20262 at ULB's Erasme Hospital. Each patient will be treated with Invisalign MA or the Herbst appliance by residents of the orthodontic program directed by P. Maria Orellana Inclusion criteria included a Class II skeletal malocclusion with an ANB greater than 4°; (In the case of a Class 2 Division 2 malocclusion, the retroclined upper incisors will be proclined to obtain an overjet allowing mandibular advancement. If the patient has a transverse deficit, palatal expansion will be performed before treatment with aligners and during treatment in herbst cases.) Class II molar and canine relationship and CVM2/CVM3 cervical vertebral maturation. Informed consent forms in the patient's native language will be submitted before the start of each treatment. Only a profile cephalometry will be taken in the patients considered for this study at the time of the initial consultation. This will avoid unnecessary radiographic exposure, and a panoramic view of each patient will be extracted from a CBCT using the FDA-approved BlueskyBio program. Aligners or Herbst appliance for orthodontic treatment will be fabricated on the basis of a 3D optical scan (Itero), after which patients will begin treatment. Levelling of the Spee curve, derotation of (pre)molars and palatal incisors in the case of class 2 division 2 malocclusion will be carried out before the mandibular advancement stage if necessary in the Aligner group. A full-face ultra-low dose CBCT scan will be performed on all included subjects before the mandibular advancement stage according to a strict protocol by a certified physician. Active mandibular advancement will be continued till a KLass I molar relationship is obtained and will be followed by 2 months without mandibular advancement to allow the mandibular condyles to take a central position in the condylar fossae. After this 2-month period, a second CBCT scan will be performed (T2), with a minimal time interval of one year between the two CBCT scans, using the same protocol. CBCTs will be acquired using a Promax Mid 90 Kv with settings of 90 kV and 8.9 mAS, and tube current modulation will be used to enable patient-specific dose reduction. After the second CBCT, orthodontic treatment will be continued until completion, and retention and regular post-treatment follow-up will be scheduled for each patient. The superposition of CBCT (T1) and (T2) images on the anterior cranial base will be used to determine exact mandibular lengthening, condylar displacement, mandibular rotation and chin displacement using the following methodology described and developed by Hugo. De Clerck in 2009.
Phase
1Span
187 weeksSponsor
Université Libre de BruxellesBrussels
Recruiting
Healthy Volunteers
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Phase
1Span
179 weeksSponsor
OnKure, Inc.Anderlecht
Recruiting
Anderlecht
Recruiting
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
Phase
2/3Span
166 weeksSponsor
PharmaMarAnderlecht
Recruiting
Prospective Evaluation of PH-impedance Tracings According to the Wingate Consensus, and Influence on GERD Classification According to the Lyon Consensus
All pH-MII performed in UZ Brussel are already reviewed manually according to the Wingate con-sensus and interpreted according to the Lyon consensus. In this study, we will prospectively categorise the reasons for discarding reflux episodes identified by automated analysis during the manual review according to the Wingate consensus, as well as the impact on different parameters related to the interpretation of pH-MII. Based on comments received to our retrospective study, we will evaluate possible confounders to the interpretation, including the indication for referral for pH-MII, symptom severity, use of PPI during pH-MII.
Phase
N/ASpan
131 weeksSponsor
Universitair Ziekenhuis BrusselAnderlecht
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Phase
3Span
387 weeksSponsor
GlaxoSmithKlineAnderlecht
Recruiting
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
Phase
1Span
153 weeksSponsor
PharmaMarAnderlecht
Recruiting